Medicare Enrolled
Dr. Hakam Khazrik, MD
Medical Oncology · Tavares, FL
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Khazrik from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Khazrik?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Khazrik
Dr. Hakam Khazrik is a medical oncology specialist in Tavares, FL, with 15 years of NPI registration. Based on federal Medicare data, Dr. Khazrik performed 6,541 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Khazrik received a total of $4,513 from 46 pharmaceutical and/or device companies across 215 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Khazrik is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 15 years of NPI registration
▲ Top 46% volume in FL
$4,513 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗6,541
Medicare services
Top 46% in FL for medical oncology
Not available
Unique patients (not deduplicated)
$11
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron sucrose injection (Venofer) An injection of iron sucrose used to replenish iron levels in the body. |
4,000 | $0 | $5 |
| Epoetin alfa injection (Procrit) for anemia An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis. |
400 | $6 | $23 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
383 | $8 | $9 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
362 | $8 | $29 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
250 | $0 | $3 |
| Anti-nausea injection (Aloxi/palonosetron) | 200 | $1 | $28 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
155 | $133 | $556 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
95 | $70 | $239 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
81 | $10 | $69 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
74 | $12 | $61 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
62 | $47 | $189 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
60 | $94 | $285 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
58 | $99 | $378 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
58 | $98 | $339 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
53 | $55 | $206 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
52 | $101 | $377 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
31 | $1 | $6 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
30 | $1 | $3 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
28 | $44 | $147 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
25 | $86 | $298 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
23 | $22 | $84 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
19 | $126 | $453 |
| Methylprednisolone injection, up to 40 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, administered in a dose of up to 40 mg. |
17 | $3 | $11 |
| Office visit for established patient An office visit for an existing patient that may not require the healthcare professional to be present. |
14 | $18 | $59 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
11 | $26 | $89 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
2.2% high complexity
78.7% medium
19.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$4,513
Total received (2022-2024)
Avg $1,504/year across 3 years
Bottom 42% in FL for medical oncology
46
Companies
215
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,806
2023
$1,665
2022
$42
Payments by company (2024)
Novartis Pharmaceuticals Corporation
$277
Celgene Corporation
$263
AstraZeneca Pharmaceuticals LP
$210
Bayer Healthcare Pharmaceuticals Inc.
$175
PFIZER INC.
$158
ABBVIE INC.
$153
Gilead Sciences, Inc.
$133
Eisai Inc.
$110
Janssen Biotech, Inc.
$103
GENZYME CORPORATION
$99
Takeda Pharmaceuticals U.S.A., Inc.
$78
Myriad Genetic Laboratories, Inc.
$73
E.R. Squibb & Sons, L.L.C.
$73
Merck Sharp & Dohme LLC
$71
Astellas Pharma US Inc
$69
Pharmacosmos Therapeutics Inc.
$56
BeiGene USA, Inc.
$54
Regeneron Healthcare Solutions, Inc.
$53
Sumitomo Pharma America, Inc.
$51
Incyte Corporation
$51
Mirati Therapeutics, Inc.
$50
ARRAY BIOPHARMA INC
$42
JAZZ PHARMACEUTICALS INC.
$40
Lilly USA, LLC
$33
PharmaEssentia USA Corporation
$32
Kite Pharma, Inc.
$30
Kyowa Kirin, Inc.
$29
Rigel Pharmaceuticals, Inc.
$26
SOBI, INC
$26
Alexion Pharmaceuticals, Inc.
$25
EMD Serono, Inc.
$24
Fennec Pharmaceuticals, Inc.
$24
Genentech USA, Inc.
$22
ADC Therapeutics America, Inc.
$21
GlaxoSmithKline, LLC.
$19
Alnylam Pharmaceuticals Inc.
$19
Blueprint Medicines Corporation
$18
Daiichi Sankyo Inc.
$16
Top 3 companies account for 26.7% of 2024 payments
All-time payments by company (2022-2024) ›
Novartis Pharmaceuticals Corporation
$449
Celgene Corporation
$395
AstraZeneca Pharmaceuticals LP
$266
Janssen Biotech, Inc.
$253
ABBVIE INC.
$202
PFIZER INC.
$201
GENZYME CORPORATION
$197
Bayer Healthcare Pharmaceuticals Inc.
$190
Merck Sharp & Dohme LLC
$169
Gilead Sciences, Inc.
$152
Eisai Inc.
$128
SOBI, INC
$121
Takeda Pharmaceuticals U.S.A., Inc.
$112
Astellas Pharma US Inc
$107
Seagen Inc.
$106
E.R. Squibb & Sons, L.L.C.
$91
Genentech USA, Inc.
$86
Pharmacyclics LLC, An AbbVie Company
$83
Kite Pharma, Inc.
$83
Pharmacosmos Therapeutics Inc.
$80
Myriad Genetic Laboratories, Inc.
$73
Mirati Therapeutics, Inc.
$67
Incyte Corporation
$65
JAZZ PHARMACEUTICALS INC.
$64
EMD Serono, Inc.
$61
Lilly USA, LLC
$61
Alexion Pharmaceuticals, Inc.
$60
BeiGene USA, Inc.
$54
Regeneron Healthcare Solutions, Inc.
$53
Sumitomo Pharma America, Inc.
$51
Blueprint Medicines Corporation
$48
ARRAY BIOPHARMA INC
$42
TerSera Therapeutics LLC
$37
Daiichi Sankyo Inc.
$33
Amgen Inc.
$33
PharmaEssentia USA Corporation
$32
Kyowa Kirin, Inc.
$29
Rigel Pharmaceuticals, Inc.
$26
Fennec Pharmaceuticals, Inc.
$24
G1 Therapeutics, Inc.
$24
ADC Therapeutics America, Inc.
$21
GlaxoSmithKline, LLC.
$19
Alnylam Pharmaceuticals Inc.
$19
Foundation Medicine, Inc.
$18
Agios Pharmaceuticals, Inc.
$15
Secura Bio, Inc.
$13
Top 3 companies account for 24.6% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AYVAKIT · Alecensa · BAVENCIO · BESREMI · BOSULIF · BRUKINSA · COPIKTRA · COSELA · Columvi · DARZALEX · DOPTELET · Doptelet · ELREXFIO · ENHERTU · ENJAYMO · EPKINLY · ERLEADA · Enhertu · FRUZAQLA · Fabhalta · GIVLAARI · ICLUSIG · IMBRUVICA · IMFINZI · JAKAFI · KEYTRUDA · KISQALI · KRAZATI · LIBTAYO · LORBRENA · LUMAKRAS · LUPRON DEPOT · LUTATHERA · Lenvima · MEKINIST · MONOFERRIC · MYRISK · NINLARO · Nubeqa · OJJAARA · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · PADCEV · PIQRAY · PLUVICTO · PROMACTA · PYRUKYND · Padcev · Pedmark · Pomalyst · Poteligeo · REBLOZYL · RYBREVANT · Rezlidhia · SARCLISA · SCEMBLIX · Stivarga · TASIGNA · TIVDAK · TUKYSA · Tecentriq · ULTOMIRIS · VENCLEXTA · VERZENIO · Venclexta · Vyloy · XALKORI · XTANDI · Xermelo · Xospata · Xtandi · Yescarta · ZEPZELCA · ZIIHERA · Zoladex
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Medical oncologists in nearby ZIP areas
14
County median income
$69,956
Nearest hospital to ZIP centroid (approximate)
ADVENTHEALTH WATERMAN
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Khazrik is a mixed practice specialist, with moderate Medicare volume, with 15 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Khazrik experienced with iron sucrose injection (venofer)?
Based on Medicare claims data, Dr. Khazrik performed 4,000 iron sucrose injection (venofer) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Khazrik receive payments from pharmaceutical companies?
Yes. Dr. Khazrik received a total of $4,513 from 46 companies across 215 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Khazrik's costs compare to other medical oncologists in Tavares?
Dr. Khazrik's average Medicare payment per service is $11. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Khazrik) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Tavares
Browse medical oncologists in Tavares ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in FL
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in FL
Which FL medical oncologists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Celgene Corporation Payments to Doctors
See all physicians who received payments from Celgene Corporation.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology